Paper Details

  1. Home
  2. Paper Details

Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.

Author: AletahaDaniel, BonelliMichael, DejacoChristian, DurechovaMartina, HusicRusmir, KerschbaumerAndreas, MandlPeter, MrakDaniel, RadnerHelga, SmolenJosef S, StiegerJutta

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Tocilizumab was superior to placebo in achieving sustained glucocorticoid-free remission, delaying time to relapse, and reducing cumulative glucocorticoid dose in patients with new onset polymyalgia rheumatica undergoing rapid glucocorticoid tapering.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Polymyalgia rheumatica is the second most common inflammatory rheumatic disease of people >50 years. Glucocorticoid therapy is highly effective, but many patients require treatment for several years. Effective glucocorticoid sparing agents are still needed. METHODS: In this double-blind...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1136/annrheumdis-2021-221126

データ提供：米国国立医学図書館（NLM）

Tocilizumab: A Potential Oasis in the Desert of Polymyalgia Rheumatica

Polymyalgia rheumatica (PMR) is a debilitating inflammatory condition primarily affecting individuals over 50 years of age. This Phase 2/3 randomized controlled trial investigates the efficacy and safety of tocilizumab, a monoclonal antibody, in treating new-onset PMR. The researchers aim to evaluate tocilizumab's potential as a glucocorticoid-sparing agent for PMR, offering an alternative approach to manage this challenging condition.

Tocilizumab: A Promising Glucocorticoid-Sparing Agent for PMR

The study found that tocilizumab was significantly superior to placebo in achieving sustained glucocorticoid-free remission in patients with new-onset PMR. Tocilizumab also demonstrated a longer time to relapse and reduced cumulative glucocorticoid dose compared to placebo. These findings suggest that tocilizumab could be a valuable tool for managing PMR, potentially reducing the need for long-term glucocorticoid therapy and its associated side effects.

Navigating the Complexities of PMR Treatment

The study emphasizes the importance of individualized treatment approaches for PMR, considering the potential benefits and risks of different therapies. Patients should work closely with their healthcare providers to determine the most appropriate treatment plan for their individual needs.

Dr. Camel's Conclusion

This Phase 2/3 trial is like a camel caravan venturing into a new oasis in the desert of PMR research. The study demonstrates the potential of tocilizumab as a promising glucocorticoid-sparing agent for PMR, offering patients with this challenging condition an alternative to long-term glucocorticoid therapy. The study paves the way for further research into the long-term efficacy and safety of tocilizumab for PMR management.

Date :
  1. Date Completed 2022-05-19
  2. Date Revised 2022-07-22
Further Info :

Pubmed ID

35210264

DOI: Digital Object Identifier

10.1136/annrheumdis-2021-221126

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.